David Shook

Insider · Chief Medical Officer · LYEL

David Shook files insider transactions with the SEC as a chief medical officer of Lyell Immunopharma. We hold 2 disclosed purchases and sales filed since 18 January 2023, 1 of them in the last 90 days.

Files for 2 companiesLYEL, NKTX
Disclosed buys and sells2 in all, 1 in the last 90 days
Last disclosure10 September 2026

Positions held

2 posts we hold — a term names its own dates; a run of filings only says when they filed

Filed 9 June 2025 — 10 September 2026Chief Medical Officer · Lyell Immunopharma 6 Form 4 lines · source: SEC Form 4
Filed 13 January 2023 — 15 January 2025Officer · Nkarta 16 Form 4 lines · source: SEC Form 4

Every transaction

22 transactions from SEC Form 4 — one row each, sort any column, open a row for the filing

Sort byOpen-market trades only22 of 22 shown


10 Sep 2026	10 Sep 2026SEC Form 4	0 d	sold on the open market	Lyell Immunopharma	500 shares	down −2.0%	down −2.0%
10 Jun 2026	11 Jun 2026SEC Form 4	1 d	sold on the open market	Lyell Immunopharma	1,977 shares	down −9.5%	down −12.8%
10 Feb 2026	11 Feb 2026SEC Form 4	1 d	was grantednot a trade	Lyell Immunopharmaderivative	50,000 shares	down −49.6%	down −50.9%
10 Feb 2026	11 Feb 2026SEC Form 4	1 d	was grantednot a trade	Lyell Immunopharmaderivative	50,000 shares	down −49.6%	down −50.9%
9 Jun 2025	11 Jun 2025SEC Form 4	2 d	was grantednot a trade	Lyell Immunopharmaderivative	43,750 shares	down −4.1%	up +27.1%
9 Jun 2025	11 Jun 2025SEC Form 4	2 d	was grantednot a trade	Lyell Immunopharma	21,900 shares	down −4.1%	up +27.1%
15 Jan 2025	17 Jan 2025SEC Form 4	2 d	sold on the open market	Nkarta	8,638 shares	up +29.9%	up +17.8%
3 Jan 2025	7 Jan 2025SEC Form 4	4 d	was grantednot a trade	Nkartaderivative	117,500 shares	up +16.4%	up +20.2%
3 Jan 2025	7 Jan 2025SEC Form 4	4 d	was grantednot a trade	Nkarta	59,000 shares	up +16.4%	up +20.2%
21 Aug 2024	23 Aug 2024SEC Form 4	2 d	was grantednot a trade	Nkarta	1,352 shares	down −45.9%	down −45.3%
15 Jul 2024	31 Jul 2024SEC Form 4	16 d	was grantednot a trade	Nkartaderivative	30,000 shares	down −58.5%	down −54.7%
15 Jul 2024	31 Jul 2024SEC Form 4	16 d	was grantednot a trade	Nkarta	23,421 shares	down −58.5%	down −54.7%
18 Jun 2024	20 Jun 2024SEC Form 4	2 d	sold on the open market	Nkarta	456 shares	down −44.8%	down −45.0%
16 Jan 2024	18 Jan 2024SEC Form 4	2 d	sold on the open market	Nkarta	3,552 shares	down −66.5%	down −65.8%
4 Jan 2024	8 Jan 2024SEC Form 4	4 d	was grantednot a trade	Nkartaderivative	112,500 shares	down −51.5%	down −72.9%
4 Jan 2024	8 Jan 2024SEC Form 4	4 d	was grantednot a trade	Nkarta	56,000 shares	down −51.5%	down −72.9%
21 Aug 2023	23 Aug 2023SEC Form 4	2 d	sold on the open market	Nkarta	1,331 shares	up +59.9%	up +57.3%
1 Jul 2023	5 Jul 2023SEC Form 4	4 d	was grantednot a trade	Nkartaderivative	208,000 shares	up +32.9%	up +37.9%
20 Jun 2023	22 Jun 2023SEC Form 4	2 d	sold on the open market	Nkarta	439 shares	down −40.2%	down −36.3%
17 Jan 2023	18 Jan 2023SEC Form 4	1 d	sold on the open market	Nkarta	175 shares	down −45.8%	down −42.3%
13 Jan 2023	18 Jan 2023SEC Form 4	5 d	was grantednot a trade	Nkartaderivative	75,000 shares	down −47.8%	down −42.3%
13 Jan 2023	18 Jan 2023SEC Form 4	5 d	was grantednot a trade	Nkarta	37,500 shares	down −47.8%	down −42.3%

Both percentages are the stock’s move, not David Shook’s return: a disclosure gives a band, never an amount, so nobody can say how much was bought or what it made. They run to the last close we hold — 11 Sep 2026, except where a name has since delisted, when the row names its own last session. We publish no close, no volume and no dollar figure behind them. 22 of the 22 rows shown carry a percentage; the rest are dashes with the reason on the row.

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.

Some filings reach us as photographs of paper rather than as a form we can read as text. Those are shown here only once they have been read and checked, so this page can hold fewer lines than the filings behind it contain. The link on every row opens the original document, which is always the full record.